Company intelligence / Profile preview

Vomaris Innovations

Tempe, Arizona, United Statesvomaris.com ↗

Ownership: Private
Employees: ~17
Development stage: Commercial

Overview

Vomaris’s FDA-cleared Procellera™ and JumpStart® Antimicrobial Wound Dressings powered by V.Dox Technology are commercially available in nine countries. Over one million wounds have been treated with their technology. Clinical studies show broad-spectrum antimicrobial efficacy—including against multidrug-resistant organisms—and support for wound healing without antibiotics[1][2].

Therapeutic areas: ImmunologyDermatology
Modalities: DeviceNon-pharmacological therapy
Industry: Consumable Medical Devices

Drug pipeline

3 assets

Procellera

Commercial

Indications: Wound healing, Infection control

2 more assets in the full pipeline.

Request access →

Partnerships

Arthrex (JumpStart® trademark registered to Arthrex)

Beyond the preview

Go deeper on Vomaris Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vomaris Innovations.

Explore the full profile